Lilly Teams Up With Boehringer Ingelheim To Boost Abemaciclib

The two big pharmas are working together in oncology in an effort to advance combination therapies in both their growing, but young oncology pipelines.

In its most recent tie-up with Boehringer Ingelheim GMBH, Eli Lilly & Co. has inked a research collaboration to test its late-stage cancer asset with an early-stage compound from its partner. The tie-up has the potential to advance both companies in the oncology space.

Lilly and BI announced July 13 that they will test Lilly's cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib with BI's insulin-like...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip